Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

61. National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort Full Text available with Trip Pro

. PMID: 28993097 Review. References Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727‐733. - - Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: $ descriptive study. The Lancet. 2020;395:507‐513. - - Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: $ retrospective (...) National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account

2021 EvidenceUpdates

62. Performance of the Pandemic Medical Early Warning Score (PMEWS), Simple Triage Scoring System (STSS) and Confusion, Uremia, Respiratory rate, Blood pressure and age >/= 65 (CURB-65) score among patients with COVID-19 pneumonia in an emergency department t Full Text available with Trip Pro

Performance of the Pandemic Medical Early Warning Score (PMEWS), Simple Triage Scoring System (STSS) and Confusion, Uremia, Respiratory rate, Blood pressure and age >/= 65 (CURB-65) score among patients with COVID-19 pneumonia in an emergency department t Performance of the Pandemic Medical Early Warning Score (PMEWS), Simple Triage Scoring System (STSS) and Confusion, Uremia, Respiratory rate, Blood pressure and age ≥ 65 (CURB-65) score among patients with COVID-19 pneumonia in an emergency (...) department triage setting: a retrospective study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item

2021 EvidenceUpdates

63. Cesarean Section or Vaginal Delivery to Prevent Possible Vertical Transmission From a Pregnant Mother Confirmed With COVID-19 to a Neonate: A Systematic Review Full Text available with Trip Pro

Cesarean Section or Vaginal Delivery to Prevent Possible Vertical Transmission From a Pregnant Mother Confirmed With COVID-19 to a Neonate: A Systematic Review Cesarean Section or Vaginal Delivery to Prevent Possible Vertical Transmission From a Pregnant Mother Confirmed With COVID-19 to a Neonate: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33681259 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable

2021 EvidenceUpdates

64. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Lancet Respir Med Actions . 2021 Mar 4;S2213-2600(21)00099-0. doi: 10.1016/S2213-2600(21)00099-0. Online ahead of print. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial , , , , , , , , Collaborators, Affiliations Expand Collaborators Sarilumab COVID-19

2021 EvidenceUpdates

65. Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain

Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain Prescrire IN ENGLISH - Spotlight ''Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain'', 23 March 2021 {1} {1} {1} | | > > > Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain NEWS UPDATE Covid-19 vaccine Ad26.CoV2S, marketed by the pharmaceutical company Janssen (part of the Johnson & Johnson group), was authorised in the European Union on 11 March 2021. What are the main data available as of mid

2021 Prescrire

66. Physical density to reduce the transmission of COVID-19 in hospital wards

, El-Daly I, Jeyaseelan L, Pearse M. Reflections from London’s Level-1 Major Trauma Centres during the COVID crisis. Tao J, Song Z, Yang L, Huang C, Feng A, Man X. Emergency management of 2019 novel coronavirus: implications for the dermatology department. British Journal of Dermatology. 2020 Jun;182(6):e195-. Wang et al. 2020. Providing uninterrupted care during COVID-19 pandemic: experience from Beijing Tiantan Hospital. Stroke and Vascular Neurology Zhou Q, Yu H, Liang ZA, Yao R, Luo FM, Liu D (...) , Wang T, Ni Z, Zhong CJ, Jin XD. Prevention and treatment system of novel coronavirus infection in medical and health institutions: experience in West China Hospital of Sichuan University. Emergency Medicine Journal. 2020 Oct 1;37(10):639-41. Evidence Snapshot: Physical density to reduce transmission of COVID-19 in hospital wards | Sax Institute 11 Zuliani et al. 2020. Organisational challenges, volumes of oncological activity and patients’ perception during the severe acute respiratory syndrome

2021 Sax Institute Evidence Check

67. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression Full Text available with Trip Pro

IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search: Search Save Email Send to Display (...) Format Share Permalink Copy Page navigation J Infect Actions . 2021 Mar 18;S0163-4453(21)00125-0. doi: 10.1016/j.jinf.2021.03.008. Online ahead of print. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10 Cutcombe Road, London SE5 9RJ, UK. 2 Centre for Rheumatic Diseases, Weston Education Centre, King's College London, 10

2021 EvidenceUpdates

68. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19? Full Text available with Trip Pro

Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19? Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19? - Annals of Emergency Medicine Login to your account Email/Username Password Remember me Don’t have an account? ACEP Member Login ACEP Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. If you don't remember your password, you can (...) reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password Email* If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password Go search Please enter a term before submitting your search. , P407-409, April 01, 2021 Powered By Mendeley Share on Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19

2021 Annals of Emergency Medicine Systematic Review Snapshots

70. COVID-19 rapid evidence summary: Sarilumab for COVID-19

COVID-19 rapid evidence summary: Sarilumab for COVID-19 COVID-19 rapid evidence summary: Sarilumab for COVID-19 Evidence summary Published: 20 January 2021 www.nice.org.uk/guidance/es34 pathways Product overview Product overview The content of this evidence summary was up to date in January 2021. New evidence may have been published since then. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA (...) ) or NICE websites for up-to-date prescribing information. Sarilumab is an interleukin-6 inhibitor. It has a marketing authorisation for moderate to severe rheumatoid arthritis in adults whose condition has not responded adequately to 1 or more disease modifying antirheumatic drugs. It is licensed for use in combination with methotrexate, or as monotherapy if methotrexate is inappropriate or not tolerated (see the summaries of product characteristics for sarilumab). Use of sarilumab for COVID-19 is off

2021 NICE COVID-19 rapid evidence summary

71. COVID-19 Strategic Preparedness and Response Plan Operational Planning Guideline

COVID-19 Strategic Preparedness and Response Plan Operational Planning Guideline 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLANNING GUIDELINE1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLAN COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLANNING GUIDELINEiv COVID-19 Strategic preparedness and response plan: Operational planning guideline WHO/WHE/2021.03 © World Health (...) relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. WHO COVID-19 Strategic preparedness and response plan: Operational planning guideline. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris?. Sales, rights and licensing

2021 WHO Coronavirus disease (COVID-19) Pandemic

72. Living Review - COVID-19: Remdesivir for Hospitalized Adults

Living Review - COVID-19: Remdesivir for Hospitalized Adults COVID-19: Remdesivir for Hospitalized Adults - A Living Review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting to the official website (...) and that any information you provide is encrypted and sent securely. Search HSR&D Search the HSRD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » COVID-19: Remdesivir for Hospitalized Adults - A Living Review Health Services Research & Development COVID-19: Remdesivir

2021 Veterans Affairs Evidence-based Synthesis Program Reports

73. Mental health outcomes of adults hospitalized for COVID-19: A living rapid review

Mental health outcomes of adults hospitalized for COVID-19: A living rapid review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting to the official website and that any information you provide is encrypted (...) and sent securely. Search HSR&D Search the HSRD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » Mental health outcomes of adults hospitalized for COVID-19: A living rapid review Health Services Research & Development Mental health outcomes of adults hospitalized

2021 Veterans Affairs Evidence-based Synthesis Program Reports

74. WHO strategic action and resource requirements to end the acute phase of the COVID-19 pandemic 2021

-General declared the novel coronavirus outbreak a public health emergency of international concern (PHEIC), WHO’s highest level of alarm under international law. As the COVID-19 pandemic evolved, the SPRP was updated in April 2020 to underline the importance of critical aspects of the public health response, and support countries to safely and sustainably transition out of the severe movement restrictions that had been put in place in some countries. As we enter 2021, it is again important that we (...) , technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVID-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts. This graphic highlights just a small selection of WHO’s work in 2020; for more information see: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/interactive-timeline 23 United Nations (UN) entities participating in UN

2021 WHO Coronavirus disease (COVID-19) Pandemic

75. COVID-19 Strategic Preparedness and Response Plan

repeating them.viii 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN ABOUT THIS DOCUMENT WHO published the first COVID-19 Strategic preparedness and response plan (SPRP) on 4 February, 2020, four days after the Director-General declared the novel coronavirus outbreak a public health emergency of international concern (PHEIC), WHO’s highest level of alarm under international law. As the COVID-19 pandemic evolved, the SPRP was updated in April 2020 to underline (...) COVID-19 Strategic Preparedness and Response Plan 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLANiv COVID-19 Strategic preparedness and response plan WHO/WHE/2021.02 © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org

2021 WHO Coronavirus disease (COVID-19) Pandemic

76. Contact tracing in the context of COVID-19

Contact tracing in the context of COVID-19 -1- Contact tracing in the context of COVID-19 Interim guidance 1 February 2021 Introduction Contact tracing – along with robust testing, isolation and care of cases – is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing mortality associated with COVID-19 1,2 . The trigger to commence contact tracing is detection of a probable or confirmed case (Figure 1). Individuals who have been in contact with this case (...) to as ‘backward tracing’) is key to detecting unrecognized chains of transmission and common points of exposure. Case investigations may be an efficient way to identify additional contacts at particularly high risk of becoming ill with COVID-19. At population level, source investigations help identify risk factors and allow development of targeted public health and social measures (PHSM). As COVID-19 vaccines begin to deploy in many countries, it remains important to enhance existing public health strategies

2021 WHO Coronavirus disease (COVID-19) Pandemic

77. CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination

. PDF document (People who are at risk of more severe disease or outcomes from COVID-19) Provincial and Territorial vaccination rollout plans While NACI provides guidance on vaccination priorities, vaccination rollout plans are province- and territory- specific. For the latest detailed vaccination rollout plans, visit this website and go to the vaccine page for your province or territory: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus- infection/prevention-risks (...) CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination V-3.0 MARCH 16, 2021 1 This advice is for health care professionals and we cannot answer individual patient queries. Those looking for further information are advised to speak to their physician, who are best placed to answer specific questions. CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination Introduction This Canadian Thoracic Society (CTS) document aims

2021 Canadian Thoracic Society

78. Triaging COVID-19 in the Emergency Department

Triaging COVID-19 in the Emergency Department TRIAGING COVID-19 IN THE EMERGENCY DEPARTMENT An Evidence Review from Penn Medicine’s Center for Evidence-based Practice February 2021 Project director: Nikhil K. Mull, MD (CEP) Lead analyst: Matthew D. Mitchell, PhD (CEP) Clinical review: Eric Bressman, MD (Medicine); S. Ryan Greysen, MD, MHS, MA, FHM (CEP); Kathleen Lee, MD (PPMC); Anna U. Morgan, MD (Medicine) Keywords: COVID-19, Emergency Department, triage EVIDENCE SUMMARY Several published (...) algorithms for appraising disease severity in patients with COVID-19 disease or determining whether they can be safely discharged from the Emergency Department (or both) were identified. None of these algorithms have been validated in clinical studies measuring their impact on patient outcomes. Among those algorithms, there is consensus that patients with low oxygen saturation should not be discharged (thresholds range from oxygen saturation of 91% to 94% without supplemental oxygen). Some

2021 Centre for Evidence-Based Practice, Penn Medicine

79. Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Position Statement for health professionals

Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Position Statement for health professionals ASCIA HP Position Statement COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA HP Position Statement COVID-19 Vaccination Introduction Vaccination is an important method to reduce the risk of developing infectious diseases, including COVID-19, caused by infection with the SARS-CoV-2 coronavirus. Immunisation occurs after the vaccine (...) stimulates the immune system to induce antibodies (immunoglobulins) and cellular immunity to protect from severe COVID-19 disease, and possibly reduce the risk of transmission of infection in the community. Whilst public health measures and restrictions that were implemented by the Australian and New Zealand governments since March 2020 have been successful in controlling the COVID-19 pandemic, vaccination programs are required throughout the world, including Australia and New Zealand. COVID-19 vaccines

2021 Australasian Society of Clinical Immunology and Allergy

80. Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals

Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination COVID-19 vaccines listed below are not live-attenuated vaccines and are safe for people with immune system disorders, including immunodeficiency and autoimmune conditions. Pfizer/BioNTech COMIRNATY COVID-19 vaccine (...) ( mRNA-based) has been provisionally approved by the Therapeutic Goods Administration (TGA), part of the Australian Government Department of Health, and by Medsafe in New Zealand for people 16 years and older. AstraZeneca/Oxford COVID-19 vaccine (viral vector) has been provisionally approved by the TGA for people 18 years and older. This vaccine is being manufactured in Australia by CSL Behring. Biocelect/Novavax COVID-19 vaccine (protein subunit) has been granted provisional determination by the TGA

2021 Australasian Society of Clinical Immunology and Allergy